source
- Kyverna reports durable responses in early cell therapy trial for autoimmune diseaseKyverna Therapeutics announced new data from its cell therapy candidate targeting an autoimmune condition, marking progress toward a potential first‑in‑class product. The results showed that a not…
- Merck’s eye-drug matches Lucentis in vision improvement but raises safety concernsMerck reported results from its Phase 2b/3 BRUNELLO trial of remigromig, a Wnt-pathway agonist for diabetic macular edema. The drug achieved non-inferior improvement in best-corrected visual acuit…